Yesterday, RBC Capital lowered the firm’s price target on Clarivate (CLVT) to $3 from $5 and keeps a Sector Perform rating on the shares. The company delivered solid free cash flow growth and guided to about 10% free cash flow growth at the midpoint in FY26, though the firm’s price target reflects the concerns around ongoing AI disintermediation risk, and execution around a potential Life Sciences and Healthcare segment sale, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLVT:
- Clarivate price target lowered to $6 from $7 at Stifel
- Clarivate price target lowered to $3.10 from $3.60 at Goldman Sachs
- Clarivate price target lowered to $2.40 from $4 at Barclays
- Midday Fly By: Home Depot reports Q4 beat, AMD and Meta expand partnership
- Clarivate Advances Subscription Model, Explores Life Sciences Divestiture